JP2018062501A - 薬物担体とするために酸化修飾による膜透過性ペプチドの創薬可能性の改善方法 - Google Patents
薬物担体とするために酸化修飾による膜透過性ペプチドの創薬可能性の改善方法 Download PDFInfo
- Publication number
- JP2018062501A JP2018062501A JP2017086216A JP2017086216A JP2018062501A JP 2018062501 A JP2018062501 A JP 2018062501A JP 2017086216 A JP2017086216 A JP 2017086216A JP 2017086216 A JP2017086216 A JP 2017086216A JP 2018062501 A JP2018062501 A JP 2018062501A
- Authority
- JP
- Japan
- Prior art keywords
- cpp
- ecp
- peptide
- dimer
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 16
- 230000004048 modification Effects 0.000 title claims abstract description 15
- 238000012986 modification Methods 0.000 title claims abstract description 15
- 230000001590 oxidative effect Effects 0.000 title claims abstract description 11
- 239000003937 drug carrier Substances 0.000 title abstract description 23
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 title abstract description 7
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 title abstract description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 114
- 239000000539 dimer Substances 0.000 claims abstract description 112
- 230000027455 binding Effects 0.000 claims abstract description 63
- 239000003814 drug Substances 0.000 claims abstract description 31
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims abstract description 12
- 150000001413 amino acids Chemical class 0.000 claims abstract description 12
- 235000001014 amino acid Nutrition 0.000 claims abstract description 10
- 229940024606 amino acid Drugs 0.000 claims abstract description 10
- 235000018417 cysteine Nutrition 0.000 claims abstract description 9
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229910000365 copper sulfate Inorganic materials 0.000 claims abstract description 6
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims abstract description 6
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims abstract description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims abstract description 4
- 125000003118 aryl group Chemical group 0.000 claims abstract description 4
- 229960001230 asparagine Drugs 0.000 claims abstract description 4
- 235000009582 asparagine Nutrition 0.000 claims abstract description 4
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 34
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 25
- 229920000642 polymer Polymers 0.000 claims description 12
- 150000003384 small molecules Chemical class 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 7
- 235000018102 proteins Nutrition 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 239000000523 sample Substances 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 230000009471 action Effects 0.000 claims description 4
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 4
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 239000002105 nanoparticle Substances 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims description 3
- 230000010189 intracellular transport Effects 0.000 claims description 3
- 239000003550 marker Substances 0.000 claims description 3
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 25
- 230000035699 permeability Effects 0.000 abstract description 11
- 230000002708 enhancing effect Effects 0.000 abstract description 5
- 108091005601 modified peptides Proteins 0.000 abstract description 3
- 230000017854 proteolysis Effects 0.000 abstract description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 abstract 1
- 229920002971 Heparan sulfate Polymers 0.000 abstract 1
- 238000002626 targeted therapy Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 109
- 210000002966 serum Anatomy 0.000 description 28
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 26
- 239000000178 monomer Substances 0.000 description 22
- 238000004128 high performance liquid chromatography Methods 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 20
- 102000004506 Blood Proteins Human genes 0.000 description 14
- 108010017384 Blood Proteins Proteins 0.000 description 14
- 238000004113 cell culture Methods 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 238000005406 washing Methods 0.000 description 12
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 11
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 11
- 201000005202 lung cancer Diseases 0.000 description 11
- 208000020816 lung neoplasm Diseases 0.000 description 11
- 238000005119 centrifugation Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000000903 blocking effect Effects 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 239000012120 mounting media Substances 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 102100024025 Heparanase Human genes 0.000 description 6
- 238000002648 combination therapy Methods 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- 238000007876 drug discovery Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 108010037536 heparanase Proteins 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 125000003396 thiol group Chemical group [H]S* 0.000 description 6
- 230000035899 viability Effects 0.000 description 6
- 238000010586 diagram Methods 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 101710191360 Eosinophil cationic protein Proteins 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 210000003855 cell nucleus Anatomy 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000034701 macropinocytosis Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000009871 nonspecific binding Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000002797 proteolythic effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical group SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102000057955 Eosinophil Cationic Human genes 0.000 description 2
- 102100040618 Eosinophil cationic protein Human genes 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 108010022901 Heparin Lyase Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000015861 cell surface binding Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940121657 clinical drug Drugs 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000562 conjugate Substances 0.000 description 2
- 230000001268 conjugating effect Effects 0.000 description 2
- 239000006059 cover glass Substances 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000003631 expected effect Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000863 peptide conjugate Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本発明の利点は併用療法(combinatorial therapy)又はセラノスティクス(theranostics)に応用できること。
実施例1 CPPecp安定性に対する改善
実施例2 CPPecpを酸化修飾してCPPecp二量体を形成する
実施例3 CPPecp二量体の細胞表面における結合及び透過
実施例4 CPPecp二量体がヘパリチン硫酸に対する結合特異性
実施例5 CPPecp二量体が潜在力のある薬物担体とする
本発明の利点は併用療法(combinatorial therapy)又はセラノスティクス(theranostics)に応用できること。
実施例1 CPPecp安定性に対する改善
実施例2 CPPecpを酸化修飾してCPPecp二量体を形成する
実施例3 CPPecp二量体の細胞表面における結合及び透過
実施例4 CPPecp二量体がヘパリチン硫酸に対する結合特異性
実施例5 CPPecp二量体が潜在力のある薬物担体とする
Claims (8)
- 複数の膜透過性ペプチドで構成されるポリマーであって、それぞれの膜透過性ペプチドは下記のNYBX1BX2BNQX3という序列で構成され、そのうちBは塩基性アミノ酸、X1はアリール基、疎水性又は無荷電の側鎖を有するアミノ酸、X2はシステイン(Cysteine)を表し、及びX3はアスパラギン(Asparagine)を表す又は存在しない。該複数の膜透過性ペプチド間はジスルフィド結合によって連結される。
- 該ポリマーは膜透過性ペプチド二量体であることを特徴とする請求項1に記載のポリマー。
- 該ポリマーはヘパリチン硫酸の選択的結合活性を有することを特徴とする請求項1又は2に記載のポリマー。
- それぞれの該膜透過性ペプチドは酸化修飾作用でジスルフィド結合を形成して連結されることを特徴とする請求項1に記載のポリマー。
- 該酸化修飾作用は過酸化水素又は硫酸銅を加えて行うことを特徴とする請求項4に記載のポリマー。
- 複合体は、請求項1〜5のいずれかに記載の膜透過性ペプチド、及び治療剤、診断プローブ、ペプチド、ヌクレオチド、アンチセンスオリゴヌクレオチド、タンパク質、ナノ粒子、リポソーム、小分子及びマーカーで構成されるグループから選択される物質を含む。
- 細胞内での輸送方法は、(a)請求項1〜3のいずれかに記載の膜透過性ペプチドポリマーを含む複合体を提供すること、及び(b)該複合体を目標細胞と培養することを含む。
- 該複合体は治療剤、診断プローブ、ペプチド、ヌクレオチド、アンチセンスオリゴヌクレオチド、タンパク質、ナノ粒子、リポソーム、小分子及びマーカーによって構成されるグループから選択される物質を含むことを特徴とする請求項7に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662407540P | 2016-10-13 | 2016-10-13 | |
US62/407,540 | 2016-10-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018062501A true JP2018062501A (ja) | 2018-04-19 |
JP6479088B2 JP6479088B2 (ja) | 2019-03-06 |
Family
ID=61903060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017086216A Active JP6479088B2 (ja) | 2016-10-13 | 2017-04-25 | 薬物担体とするために酸化修飾による膜透過性ペプチドの創薬可能性の改善方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US10526369B2 (ja) |
JP (1) | JP6479088B2 (ja) |
CN (1) | CN107955074B (ja) |
TW (1) | TWI648291B (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI740342B (zh) * | 2019-12-31 | 2021-09-21 | 傑安生技股份有限公司 | 胜肽CPPecp二聚體用於治療皮膚炎之用途 |
WO2022141500A1 (zh) * | 2020-12-31 | 2022-07-07 | 妍禾生医科技股份有限公司 | 一种可与活性物质合并使用并提升该活性物质效能的细胞穿透胜肽用于皮肤保健之用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110280798A1 (en) * | 2010-05-14 | 2011-11-17 | National Tsing Hua University | Cell Penetrating Peptides for Intracellular Delivery |
US20120214730A1 (en) * | 2008-05-21 | 2012-08-23 | National Tsing Hua University | Method of using heparin binding motif for treating asthma |
US20130315828A1 (en) * | 2012-05-23 | 2013-11-28 | National Tsing Hua University | Kit and method of use of targeting peptide for diagnosis and therapy of cancer |
US20140072574A1 (en) * | 2012-09-10 | 2014-03-13 | National Tsing Hua University | Methods of using immunomodulating peptide for treating or preventing inflammatory related diseases |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2551756B2 (ja) * | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
US5316935A (en) * | 1992-04-06 | 1994-05-31 | California Institute Of Technology | Subtilisin variants suitable for hydrolysis and synthesis in organic media |
GB2307476A (en) * | 1995-06-06 | 1997-05-28 | Procter & Gamble | Peptides with anti-adherence activity for use in oral care compositions |
US7595374B1 (en) | 2008-05-21 | 2009-09-29 | National Tsing Hua University | Heparin binding motif and use thereof |
-
2017
- 2017-02-10 TW TW106104478A patent/TWI648291B/zh active
- 2017-04-06 US US15/480,414 patent/US10526369B2/en active Active
- 2017-04-25 JP JP2017086216A patent/JP6479088B2/ja active Active
- 2017-05-12 CN CN201710335258.0A patent/CN107955074B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120214730A1 (en) * | 2008-05-21 | 2012-08-23 | National Tsing Hua University | Method of using heparin binding motif for treating asthma |
US20110280798A1 (en) * | 2010-05-14 | 2011-11-17 | National Tsing Hua University | Cell Penetrating Peptides for Intracellular Delivery |
US20130315828A1 (en) * | 2012-05-23 | 2013-11-28 | National Tsing Hua University | Kit and method of use of targeting peptide for diagnosis and therapy of cancer |
US20140072574A1 (en) * | 2012-09-10 | 2014-03-13 | National Tsing Hua University | Methods of using immunomodulating peptide for treating or preventing inflammatory related diseases |
Non-Patent Citations (4)
Title |
---|
BIOMED RES. INT., vol. Vol. 2013, Article ID 170398, JPN6018023035, pages 12 pages * |
BIOMED RES. INT., vol. Vol. 2015, Aiticle ID 237969, JPN6018023033, pages 15 pages * |
FEBS LETT., vol. Vol. 286, No. 1, 2, JPN6018023032, 1991, pages pp. 125-128 * |
PLOS ONE, vol. Vol. 8, Issue 3, JPN6018023034, 2013, pages e57318 (pp. 1-13) * |
Also Published As
Publication number | Publication date |
---|---|
US10526369B2 (en) | 2020-01-07 |
US20180105556A1 (en) | 2018-04-19 |
TWI648291B (zh) | 2019-01-21 |
JP6479088B2 (ja) | 2019-03-06 |
CN107955074A (zh) | 2018-04-24 |
CN107955074B (zh) | 2021-07-13 |
TW201813973A (zh) | 2018-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cho et al. | Development of a novel imaging agent using peptide-coated gold nanoparticles toward brain glioma stem cell marker CD133 | |
Subramanian et al. | Target-specific delivery of doxorubicin to retinoblastoma using epithelial cell adhesion molecule aptamer | |
Ahmed et al. | Peptide arrays for screening cancer specific peptides | |
Shi et al. | Liposomes combined an integrin αvβ3-specific vector with pH-responsible cell-penetrating property for highly effective antiglioma therapy through the blood–brain barrier | |
Sadeqzadeh et al. | Combined MUC1-specific nanobody-tagged PEG-polyethylenimine polyplex targeting and transcriptional targeting of tBid transgene for directed killing of MUC1 over-expressing tumour cells | |
Redko et al. | Toward the development of a novel non-RGD cyclic peptide drug conjugate for treatment of human metastatic melanoma | |
Thomas et al. | Dendrimer-based tumor cell targeting of fibroblast growth factor-1 | |
JP5677454B2 (ja) | 細胞内ターゲット結合用二座ペプチドバインダー | |
CN101146822A (zh) | EphB受体结合肽 | |
JP5677453B2 (ja) | Bpbベースのカーゴ運搬システム | |
Chen et al. | A heparan sulfate‐binding cell penetrating peptide for tumor targeting and migration inhibition | |
JP6479088B2 (ja) | 薬物担体とするために酸化修飾による膜透過性ペプチドの創薬可能性の改善方法 | |
CN107223136B (zh) | 一种将抗体导入细胞内的方法 | |
Wang et al. | The weak link: optimization of the ligand–nanoparticle interface to enhance Cancer Cell Targeting by Polymer Micelles | |
Pesarrodona et al. | Engineering a nanostructured nucleolin-binding peptide for intracellular drug delivery in triple-negative breast cancer stem cells | |
Leiske et al. | Zwitterionic amino acid-derived polyacrylates as smart materials exhibiting cellular specificity and therapeutic activity | |
Li et al. | Novel strategy utilizing extracellular cysteine-rich domain of membrane receptor for constructing d-peptide mediated targeted drug delivery systems: a case study on Fn14 | |
Pallerla et al. | Design of a doxorubicin-peptidomimetic conjugate that targets HER2-positive cancer cells | |
Grover et al. | CD44 and CD133 aptamer directed nanocarriers for cancer stem cells targeting | |
Cerezo-Magaña et al. | Proteoglycans: a common portal for SARS-CoV-2 and extracellular vesicle uptake | |
Zhang et al. | Targeted peptide-Au cluster binds to epidermal growth factor receptor (EGFR) in both active and inactive states: a clue for cancer inhibition through dual pathways | |
Wang et al. | Boosting the theranostic effect of liposomal probes toward prominin-1 through optimized dual-site targeting | |
CN107326028B (zh) | 可与cd123结合的核酸适配体及其靶向载药系统的构建与应用 | |
US11535654B2 (en) | Fusion protein or conjugated protein, intracellular delivery carrier, partial peptide, cell membrane permeation enhancer, DNA, and vector | |
Ghaemi et al. | Cell-Penetrating and Enzyme-Responsive Peptides for Targeted Cancer Therapy: Role of Arginine Residue Length on Cell Penetration and In Vivo Systemic Toxicity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20180706 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180706 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180731 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181030 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181219 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190205 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190205 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6479088 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |